BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innovative Cambridge Company Innova Biosciences Secures Prestigious Development of Prototype Grant from the Technology Strategy Board


5/15/2012 11:06:55 AM

May 15, 2012 -- Innova Biosciences (Cambridge, UK), inventor of 'Lightning-Link®', the world’s easiest to use antibody labelling technology, is pleased to announce it has been awarded a development of prototype grant circa £210,000 by the Technology Strategy Board, with matched company funding of approximately £250,000, to develop novel nanoparticle products for diagnostics applications.

The growing diagnostic market requires nanoparticles that have been linked to antibodies, but the methods for creating these hybrid reagents are complex. The Technology Strategy Board grant, awarded through its Smart programme, will allow Innova to develop high quality reagents using much simpler linking technologies. The use of nanoparticles in life sciences, including diagnostics, is a high value sector and the award of the grant will extend Innova’s penetration into this industry.

Nick Gee (CEO of Innova Biosciences) comments ‘The award of the grant in such a competitive environment underlines Innova’s excellent track record and its on-going commitment to innovation. We expect that the products and technologies emerging from this new programme will transform the way in which nanoparticle reagents are created in the future.

About Innova Biosciences Limited

Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova's business are Lightning-Link® and InnovaCoat™ technologies that simplify the production of antibody-based reagents. The expanding Lightning-Link® and InnovaCoat™ portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see http://www.innovabiosciences.com.

About the Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency, working to create economic growth by ensuring that the UK is a global leader in innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

Managed by the Technology Strategy Board, the Smart scheme offers funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge.

http://www.innovateuk.org/deliveringinnovation/smart.ashx



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES